Merck (MRK) said Thursday that its late-stage study evaluating winrevair against placebo in adults recently diagnosed with pulmonary arterial hypertension functional class II or III at intermediate or high risk of disease progression will be stopped early.
The company said the decision to stop the study was based on the positive results of the interim analysis of another late-stage trial known as Zenith, as well as review of all data from the winrevair clinical program to date.
Merck said findings from the study will be available later this year and presented at a future medical congress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.